Abuse potential refers to the likelihood for a drug to be used in nonmedical situations for its positive psychoactive effects. PRA Health Sciences’ Early Development Services group offers expert services to measure abuse potential of investigational drugs by performing human abuse liability (HAL) studies, which are required for drugs that affect the central nervous system, drugs similar to known drugs with abuse potential, and drugs with positive psychoactive effects. This poster discusses what a HAL study is and the challenges posed to study teams and medical writers by the complexity and unique design of these Phase I clinical trials.
Explore related content and topics
Newsletter
Industry Watch
In the first week of December, Industry Watch brings our readers news of promising developments in oncology. There’s a machine learning method being…
Poster
A Retrospective Analysis of the Effects of Protocol Design on Completion Rates in Outpatient Clinical Trials in Subjects with Schizophrenia or Schizoaffective Disorder
Subject attrition from randomized Schizophrenia trials is a significant problem and has been found in a meta-analysis to be as high as 76%. The…
Case Study
Program Challenges Strengthen Partnership
PRA Health Sciences was selected to conduct a global program of studies that targeted 2,200+ patients with multiple sclerosis (MS). Although there…